Literature DB >> 20922801

Prognostic model for survival in patients with early stage cervical cancer.

Petra Biewenga1, Jacobus van der Velden, Ben Willem J Mol, Lukas J A Stalpers, Marten S Schilthuis, Jan Willem van der Steeg, Matthé P M Burger, Marrije R Buist.   

Abstract

BACKGROUND: In the management of early stage cervical cancer, knowledge about the prognosis is critical. Although many factors have an impact on survival, their relative importance remains controversial. This study aims to develop a prognostic model for survival in early stage cervical cancer patients and to reconsider grounds for adjuvant treatment.
METHODS: A multivariate Cox regression model was used to identify the prognostic weight of clinical and histological factors for disease-specific survival (DSS) in 710 consecutive patients who had surgery for early stage cervical cancer (FIGO [International Federation of Gynecology and Obstetrics] stage IA2-IIA). Prognostic scores were derived by converting the regression coefficients for each prognostic marker and used in a score chart. The discriminative capacity was expressed as the area under the curve (AUC) of the receiver operating characteristic.
RESULTS: The 5-year DSS was 92%. Tumor diameter, histological type, lymph node metastasis, depth of stromal invasion, lymph vascular space invasion, and parametrial extension were independently associated with DSS and were included in a Cox regression model. This prognostic model, corrected for the 9% overfit shown by internal validation, showed a fair discriminative capacity (AUC, 0.73). The derived score chart predicting 5-year DSS showed a good discriminative capacity (AUC, 0.85).
CONCLUSIONS: In patients with early stage cervical cancer, DSS can be predicted with a statistical model. Models, such as that presented here, should be used in clinical trials on the effects of adjuvant treatments in high-risk early cervical cancer patients, both to stratify and to include patients.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20922801     DOI: 10.1002/cncr.25658

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  53 in total

1.  MicroRNAs used as novel biomarkers for detecting cancer metastasis.

Authors:  Chunshan Han; Haixiang Yu; Lening Zhang; Xiaoli Li; Yonggang Feng; Hua Xin
Journal:  Tumour Biol       Date:  2014-10-31

2.  Molecular biomarkers in the decision of treatment of cervical carcinoma patients.

Authors:  A Valenciano; L A Henríquez-Hernández; M Lloret; B Pinar; P C Lara
Journal:  Clin Transl Oncol       Date:  2013-02-22       Impact factor: 3.405

Review 3.  Early Cervical Cancer: Current Dilemmas of Staging and Surgery.

Authors:  Tiffany Zigras; Genevieve Lennox; Karla Willows; Allan Covens
Journal:  Curr Oncol Rep       Date:  2017-08       Impact factor: 5.075

4.  miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1.

Authors:  Fenfen Wang; Yang Li; Jiansong Zhou; Junfen Xu; Chanjuan Peng; Feng Ye; Yuanming Shen; Weiguo Lu; Xiaoyun Wan; Xing Xie
Journal:  Am J Pathol       Date:  2011-09-21       Impact factor: 4.307

5.  Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer.

Authors:  Beatrice Cormier; John P Diaz; Karin Shih; Rachael M Sampson; Yukio Sonoda; Kay J Park; Khaled Alektiar; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2011-05-13       Impact factor: 5.482

6.  Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer.

Authors:  Shihong Cao; Weiliang Liu; Feng Li; Weipin Zhao; Chuan Qin
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

7.  Expression and prognostic significance of TAp73 and ΔNp73 in FIGO stage I-II cervical squamous cell carcinoma.

Authors:  Weipei Zhu; Xiaohong Pan; Zhujuan Yang; Pengfei Xing; Yongshen Zhang; Feng Li; Xueguan Lu
Journal:  Oncol Lett       Date:  2015-03-17       Impact factor: 2.967

8.  Feedback between E2F1 and CIP2A regulated by human papillomavirus E7 in cervical cancer: implications for prognosis.

Authors:  Xiao Wang; Peng Gao; Meng Wang; Jing Liu; Jiaxiang Lin; Shule Zhang; Yiwei Zhao; Jingwen Zhang; Wei Pan; Zeyu Sun; Feifei Sun; Weiming Zhao; Chenghao Guo; Qingwei Wang
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

9.  The association between -1304T>G polymorphism in the promoter of mitogen-activated protein kinase kinase 4 gene and the risk of cervical cancer in Chinese population.

Authors:  Min Hu; Jian Zheng; Liyuan Zhang; Lan Jiang; Yonghe You; Mingjun Jiang; Hua Li
Journal:  DNA Cell Biol       Date:  2012-02-15       Impact factor: 3.311

10.  Survey of the clinical practice pattern of using sentinel lymph node biopsy in patients with gynecological cancers in Japan: the Japan Society of Gynecologic Oncology study.

Authors:  Shinichi Togami; Hiroaki Kobayashi; Hitoshi Niikura; Muneaki Shimada; Nobuyuki Susumu; Tomohito Tanaka; Yoshito Terai; Tomoyuki Nagai; Tsukasa Baba; Hideaki Yahata; Wataru Yamagami; Ken Yamaguchi; Tsuyoshi Yamashita; Nobuo Yaegashi; Hidetaka Katabuchi; Daisuke Aoki
Journal:  Int J Clin Oncol       Date:  2021-03-25       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.